Regulatory Services
Medical device misbranding under the FD&C Act covers far more than physical label defects. Every claim your company makes about a device — in the package insert, on your website, in a brochure, or in a social post — is subject to FDA's labeling and promotion regulations. We review device labels, promotional claims, and advertising copy against 21 CFR 801 requirements before they reach FDA reviewers or enforcement staff.
Get a Labeling ReviewWhy This Matters
Under Section 502 of the FD&C Act, a device is misbranded if its labeling is false or misleading, if it lacks adequate directions for use, if its required elements are missing or incorrect, or if it is promoted for a use other than the one for which it was cleared or approved. Misbranding does not require intent — a technically accurate but incomplete label or an enthusiastic marketing claim that goes beyond the cleared indication can each constitute misbranding.
FDA's definition of "labeling" is intentionally broad. It includes the physical label, the Instructions for Use, product brochures, website pages, press releases, conference presentations, social media, and any other written or graphic material that accompanies the device or is used to supplement its promotion. Companies that treat labeling compliance as limited to the printed label routinely expose themselves to enforcement risk through their marketing materials.
Promotion beyond the cleared or approved intended use is the fastest route from a marketing department to a Warning Letter. Under FDA's intended use doctrine, the claims a company makes about a device — not just how the device is used clinically — define its intended use. If a company promotes a device cleared for one indication for a broader use, FDA may determine that the device has been given a new intended use, making it misbranded and potentially requiring a new premarket submission.
The claims trap operates in subtle ways: using patient outcome language that implies clinical benefit beyond the cleared indication, citing clinical data from studies FDA did not review, making comparative or superiority claims without adequately substantiated data, and describing an intended user population broader than the cleared one. We identify these vulnerabilities before FDA does.
Pre-launch label lock: Before printing labels or publishing marketing materials for a new device or cleared indication, a labeling review identifies compliance gaps before they reach FDA. Changes after launch — particularly if FDA has already seen the device at a trade show or in a submission — are costlier and harder to explain.
Marketing campaign review: When launching a new campaign, entering a new market, or updating promotional materials for a cleared device, a claim review confirms that the new materials stay within the cleared indication and do not imply new uses.
Post-483 or Warning Letter remediation: When FDA has cited labeling or promotion deficiencies in an inspection observation or a Warning Letter, we prepare a corrective action plan and revised materials that directly address each cited deficiency. See our FDA 483 Response service for enforcement context.
Yes. Under the FD&C Act, labeling includes all written, printed, or graphic material that accompanies the device or is used to supplement or explain the device — including company websites, brochures, social media posts, and any materials available at the point of sale. If your website makes claims about the device's intended use, indications, or performance, it is labeling subject to 21 CFR 801 requirements.
It depends. Citing data consistent with the cleared or approved intended use and labeling is permissible. Citing data to support claims that go beyond the cleared indications — or to imply the device is safe and effective for an unapproved use — constitutes off-label promotion. FDA may view such promotion as evidence of a new intended use, which can trigger misbranding and require a new premarket submission.
FDA's Office of Regulatory Affairs and CDRH can issue an Untitled Letter (informal) or Warning Letter (formal enforcement action) requiring you to stop the promotion and submit a corrective action plan. Warning Letters are publicly posted and can affect your standing with investors, distributors, and healthcare providers. Post-Warning Letter advertising review commitments must be met on the schedule FDA sets — typically 15 business days for initial response.
Yes. Exemption from premarket 510(k) notification does not exempt a device from labeling requirements under 21 CFR 801 or from establishment registration and device listing requirements. Every device introduced into US commerce must have adequate labeling, an accurate device listing, and an active establishment registration regardless of premarket pathway. See our FDA Device Listing & Registration service for details.
Get Started
FDA enforcement for misbranding and off-label promotion is active across all device classes. A pre-launch labeling review costs a fraction of a Warning Letter response — and it keeps your clearance intact and your marketing team on the right side of the regulations.